These are intriguing, hypothesis-generating data. Unexplored research area GLP-1 receptor agonists have been approved to treat diabetes since 2005 and obesity since 2014
This multifactorial approach resulted in the manifestation of typical clinical HFpEF features, including ventricular hypertrophy, increased collagen deposition and fibrosis, elevated blood pressure, and diastolic dysfunction
Mentally, its only affected me in a positive way
Demand for semaglutide (Ozempic) and tirzepatide (Mounjaro) has soared to the point of shortages , prompting multiple manufacturing site expansions
Much of the reported 40% lean mass loss with GLP-1 use is coming from the liver, explained exercise physiologist Keith Baar, a professor of Neurobiology, Physiology and Behavior and Physiology and Membrane Biology